News

  • 05/11/2012 Medigene reports financial and operating results for first quarter of 2012 more…
  • 05/07/2012 Medigene Receives EUR 5 Million Milestone Payment from Astellas more…

Webcast

Webcast of the analyst call

regarding the publication of
the 3 Months Report 2012
on May 11, 2012 at 3:30 pm CEST

  • One2
  • 17 veregen

Products / Pipeline

Research Clinical Development Market

Eligard®

Medigene participates in selling Eligard®, a drug used to treat prostate cancer marketed by AstellasPharma.

Further information …

Veregen®

Medigene is responsible for the clinical development of Veregen®, for which it obtained approval, and which is used in the treatment of genital warts. The ointment is marketed globally by business partners.

Further information …

EndoTAG®-1

Medigene has successfully completed two Phase II clinical trials for EndoTAG®-1, a drug candidate for the treatment of pancreatic cancer and triple-negative breast cancer.

Further information …

RhuDex®

Medigene is developing RhuDex® for the treatment of auto-immune diseases, such as rheumatoid arthritis.

Further information …

AAVLP

Medigene is currently conducting research into the application of AAVLP technology for the treatment of cancer and viral infections, and is examining the possibility of using AAV libraries to systematically identify suitable vaccine candidates.

Further information …
For more information on our products, just move your mouse over the bars.

Conference

  • 06/06/2012 – 06/09/2012 // Berlin, Germany EULAR Annual European Congress of Rheumatology
  • 06/18/2012 – 06/21/2012 // Boston, USA 2012 BIO International Convention

„The results achieved in the first months of 2012 confirm the positive development of our focused activities. We are making progress in our portfolio projects and feel confirmed in the pursuit of our strategy. “ Dr. Frank Mathias, Chief Executive Officer